Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharmacological Prevention of Post-traumatic Intrusions (TRAUMA-PRO)
NCT04508166Completed
- Sponsor
- Psychiatrische Universitätsklinik Zürich
- Start
- Oct 2021
- Primary completion
- Jan 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, double-blind trial of dexmedetomidine and sodium oxybate in post-traumatic stress disorder (PTSD), sponsored by Psychiatrische Universitätsklinik Zürich. Primary endpoint: Frequency of intrusive memories at 3 weeks. Started Oct 2021; status: completed.
02
Drugs
dexmedetomidinesodium oxybate
03
Conditions
post-traumatic stress disorder (PTSD)
Beyond the preview
Go deeper on NCT04508166.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04508166.